Myhealthchecked Share Discussion Threads

[hazl] 22/9/2022 18:58

Not neccessarily mike....'share price will languish'.

I rather think a lot depends , in the short and medium term, on the general market situation....politics,interest rates and everything else.

Perhaps we will have to speculate and leave it to wait and see mode.
So far they have done well ....I am glad they are not just relying on Amazon.

Dyson changed his mind quickly on that from memory,though I'm sure it suits some people.

Great board today!

[mike2042] 22/9/2022 18:51

The hesitation to state any type of forward earnings forecast I think has not been interpreted well. Without a view from the board about the company’s future earning potential the share price will languish, it’s a debt free high earning company sitting on a cash pile with 10 - 15 new product launches. There MUST be sales forecasts somewhere!!

[hazl] 22/9/2022 18:49

From R's post.


'1. Looking to stock wellness tests in multi grocery outlets with pharmacies on site, Tesco was mentioned.'

Sounds much better to me.

[hazl] 22/9/2022 18:46

I believe you can watch it back?
Anybody know?

[hazl] 22/9/2022 18:45

Thank goodness some of you were able to report back.
I was buying a new car today(second hand) and committed elsewhere.

Thanks especially to Relliott's posts good to get the detail.

[dual] 22/9/2022 18:39

You can view the slides here:https://tinyurl.com/zbsee8yb

[dual] 22/9/2022 18:34

The new rapid tests line up looks very good and they will sell well. Vitamin D, Iron deficiency & thyroid tests are needed by most adults.Just hope they are competitively priced and available in Boots next to the Vitamin tablets very soon.

[relliott10] 22/9/2022 18:09

Laura Moore, founder of Nell Health, left the board of MHC in April 2022. I'm not reading too much into it. They seem happy with the acquisition.

[mr macgregor] 22/9/2022 17:57

I think it will make a big difference when the family of tests appears on shop shelves and I’m glad that intention was illustrated in the talk.
The decision to close the lab was explained well, less so the Nell Health milestone failure. It can’t have been the revenue target related to 2022 as FY hasn’t yet ended. It must have been ‘other operational criteria’ and I can understand why they may not want to divulge.

[relliott10] 22/9/2022 17:54

I was very impressed. Well worth a watch. Lots packed into the presentation but a few takeaways:

1. Looking to stock wellness tests in multi grocery outlets with pharmacies on site, Tesco was mentioned.
2. Sector to grow to £16 billion by 2027.
3. Agree with Billy, new range looks excellent, with three tiers, priced accordingly. DNA tests, blood tests, LFTs (for non-covid conditions.)
4. Marketing will increase when portfolio fully launched.
5. M&A activity expected in 2023 with earnings enhancing targets.

[billy3] 22/9/2022 17:41

Here is the original agreement with Nell Health......


Transaction details

The initial consideration comprises GBP1.202m to be paid upfront upon completion, along with a deferred consideration element of up to GBP1.0m subject to agreed performance milestones being met. The initial consideration is to be satisfied by the issue of 27,842,931 new ordinary shares of 0.1p each ("Initial Consideration Shares") in the capital of the Company at a price of 4.1375p per share. This represents a premium of 14.9 % to the closing mid-market price of 3.6 pence on 25 June 2021, the latest practicable date prior to the signing of the sale & purchase agreement.

The Initial Consideration Shares will be subject to a Lock In for a period of six months from Completion for 15,955,087 shares and 12 months from Completion for 11,887,844 shares which will be held by members of Nell Health's management. Completion is expected to take place on 2 July 2021, being the date of Admission.

The deferred consideration is payable against the achievement of revenue targets ranging from GBP0.8m to GBP1.6m for 2022 together with other operational criteria including new test development, commercialisation targets and developments to the existing technology platform. The deferred consideration will be satisfied in new Ordinary Shares ("Deferred Consideration Shares") at a price based on the the average mid-market closing price of ordinary shares over the period of 45 days immediately preceding the date of their allotment.

The Deferred Consideration Shares will be subject to a Lock In for a period of between six and twelve months from allotment.

[atlantic57] 22/9/2022 17:30

I am listening what I have heard to date.

Negatives

When asked why they did not pay out the 1 million pound re the acquisition , she was very very vague.

Not helpful

Positives

Exciting new products and does seem very enthusiastic about future prospects

[billy3] 22/9/2022 17:04

Anyone else watching the investor meet at the moment ?

New range looks really good.

[dillydally2] 22/9/2022 10:48

Toop is the next baggerv

[tia01] 22/9/2022 10:48

Hopefully the meeting later sheds some light on peoples concerns. Money in the bank is healthy in this market so MHC are in a strong position compared to other companies

[hazl] 22/9/2022 07:45

As graybeard says we have the investormeet if people are around.

[hazl] 22/9/2022 07:41

Yes we have a good billboard and sensible observations.

[mr macgregor] 21/9/2022 20:36

Last Annual Report shows 21 staff handling millions of covid tests! Edit: in presentation Penny said there are currently only12 staff following lab closure! They can’t do everything and my interpretation of their strategy has been to maximize the covid opportunity (windfall) while gradually pivoting to longer term areas of healthcare. I suspect the covid revenues have continued longer and are tying up staff for longer than they expected hence I’m not bleating about the scant information on new tests at this stage of the game. OK the covid business post PCR testing is not very profitable but cash in the bank keeps going up which is fine by me in the current environment.

[billy3] 21/9/2022 18:20

Space.

Can you please stop banging on about the share price. We knows it’s important. But almost every post is a repeat of “even if they make
Billions the share price will drop back and MMs won’t let it rise etc etc. “.
Followed by ‘look it’s dropped again on good news as expected’.

We get it. Daily.

[donaferentes] 21/9/2022 17:25

Yes, but not so rosy when you compare H1 22 with H2 21.

[hazl] 21/9/2022 15:33

I also admire the fact they are right on trend.
Individual healthcare has been known as a buzzword or phrase for some time.

[hazl] 21/9/2022 11:38

Relliot I share some of your conerns about the market as a whole.

People will probably not have much money in their pockets for wellness tests if things get very bad.
However,they have cash to see them through,depending on the time scales of a recession.

What I'm saying is don't blame them for general market woes,on extreme ecomomic and political macro events.

Sure we are here to consider our investment decision, but I never put a fortune into smaller start ups so am prepared to see them through the harsh times IF I believe in their management going forward.

Their turnover and cash is enough to give them merit for now,in my book.
As to outlook, supernumerary by implication, is correct that we don't know yet of anything tangible,however I can remember before these continuing good results,people here,pestering about 'new tests' when are they coming and so on.
They kept reiteraring that the virus was over,move on and so on.

As time passed...surprise surprise...management played it well and posters were wrong.
Now I am giving them the benefit of the doubt.
Indeed it really is upto the individual

[graybeard1] 21/9/2022 11:26

Super - there's the InvestorMeet briefing tomorrow. Most likely that'll put some meat on the bones. If you're wanting more, put in a question for them to answer